BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 15921532)

  • 1. APOBEC3G & HTLV-1: inhibition without deamination.
    Strebel K
    Retrovirology; 2005 May; 2():37. PubMed ID: 15921532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOBEC3G targets human T-cell leukemia virus type 1.
    Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
    Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
    Holmes RK; Koning FA; Bishop KN; Malim MH
    J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary function of the two catalytic domains of APOBEC3G.
    Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
    Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recent advances in the study of mechanism of APOBEC3G against virus].
    Zhu YP; Jiang JD; Peng ZG
    Yao Xue Xue Bao; 2014 Jan; 49(1):30-6. PubMed ID: 24783502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
    Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
    J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.
    Suspène R; Sommer P; Henry M; Ferris S; Guétard D; Pochet S; Chester A; Navaratnam N; Wain-Hobson S; Vartanian JP
    Nucleic Acids Res; 2004; 32(8):2421-9. PubMed ID: 15121899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons.
    Jost S; Turelli P; Mangeat B; Protzer U; Trono D
    J Virol; 2007 Oct; 81(19):10588-96. PubMed ID: 17652382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.
    Nguyen DH; Gummuluru S; Hu J
    J Virol; 2007 May; 81(9):4465-72. PubMed ID: 17314171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G.
    Kremer M; Schnierle BS
    Curr HIV Res; 2005 Oct; 3(4):339-44. PubMed ID: 16250885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
    Bishop KN; Holmes RK; Malim MH
    J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
    Goncalves J; Santa-Marta M
    Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
    Franca R; Spadari S; Maga G
    Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the role of Vif in HIV-1 replication.
    Schröfelbauer B; Yu Q; Landau NR
    AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action.
    Santa-Marta M; Aires da Silva F; Fonseca AM; Rato S; Goncalves J
    Mol Immunol; 2007 Jan; 44(4):583-90. PubMed ID: 16580072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
    Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.
    Derse D; Hill SA; Princler G; Lloyd P; Heidecker G
    Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2915-20. PubMed ID: 17299050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Marin M; Rose KM; Kozak SL; Kabat D
    Nat Med; 2003 Nov; 9(11):1398-403. PubMed ID: 14528301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.